NEVVI Medicare utilization intelligence
or

← back

Provider profile

GORREBEECK, ALLISON MD

Hematology-Oncology · NPI 1467548628 · AUSTIN, TX

1
Groups
64
Codes · 2024
81,883
Disclosed services

GORREBEECK, ALLISON is a Hematology-Oncology in AUSTIN, TX, a member of 1 medical group, who billed 64 distinct codes to Medicare Part B in 2024.

Groups: TEXAS ONCOLOGY PA (DALLAS, TX)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

81,883
disclosed services
64
codes billed to Medicare Part B
Prior year · CY2023 81,644 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9267 Injection, paclitaxel, 1 mg
J1453 Injection, fosaprepitant, 1 mg
J1756 Injection, iron sucrose, 1 mg
J9271 Injection, pembrolizumab, 1 mg
Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J2469 Injection, palonosetron hcl, 25 mcg
J1626 Injection, granisetron hydrochloride, 100 mcg
96375 Injection of additional new drug or substance into vein
J9045 Injection, carboplatin, 50 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
36415 Insertion of needle into vein for collection of blood sample
80053 Blood test, comprehensive group of blood chemicals
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3
96413 Administration of chemotherapy into vein, 1 hour or less
J3475 Injection, magnesium sulfate, per 500 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96417 Administration of additional new drug or substance into vein, 1 hour or less
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96415 Administration of chemotherapy into vein, each additional hour
J1200 Injection, diphenhydramine hcl, up to 50 mg
M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
83615 Lactate dehydrogenase (enzyme) level
83735 Magnesium level
J3480 Injection, potassium chloride, per 2 meq
J3490 Unclassified drugs
82784 Gammaglobulin (immune system protein) measurement
83540 Iron level
83550 Iron binding capacity
82728 Ferritin (blood protein) level
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96372 Injection of drug or substance under skin or into muscle
J7030 Infusion, normal saline solution , 1000 cc
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
85055 Reticulated (young) platelet measurement
J3489 Injection, zoledronic acid, 1 mg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
84443 Blood test, thyroid stimulating hormone (tsh)
83521 Measurement of immunoglobulin light chains
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
82378 Carcinoembryonic antigen (cea) protein level
96360 Infusion into a vein for hydration, 31-60 minutes
96361 Infusion into a vein for hydration, each additional hour
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
85007 Microscopic examination for white blood cells with manual cell count
85027 Complete blood cell count (red cells, white blood cell, platelets), automated test
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
82607 Cyanocobalamin (vitamin b-12) level
84439 Thyroxine (thyroid chemical), free
84481 Thyroid hormone, t3 measurement, free
96523 Irrigation of implanted venous access drug delivery device
82232 Beta-2 microglobulin (protein) level
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
82746 Folic acid level, serum
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99195 Drawing of blood for a medical problem
85045 Red blood count, automated test
G6015 Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.